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Abstract: Animals that specialise in blood feeding have particular challenges in obtaining their meal,
whereby they impair blood hemostasis by promoting anticoagulation and vasodilation in order to
facilitate feeding. These convergent selection pressures have been studied in a number of lineages,
ranging from fleas to leeches. However, the vampire bat (Desmondus rotundus) is unstudied in regards
to potential vasodilatory mechanisms of their feeding secretions (which are a type of venom). This is
despite the intense investigations of their anticoagulant properties which have demonstrated that
D. rotundus venom contains strong anticoagulant and proteolytic activities which delay the formation
of blood clots and interfere with the blood coagulation cascade. In this study, we identified and
tested a compound from D. rotundus venom that is similar in size and amino acid sequence to human
calcitonin gene-related peptide (CGRP) which has potent vasodilatory properties. We found that
the vampire bat-derived form of CGRP (i.e., vCGRP) selectively caused endothelium-independent
relaxation of pre-contracted rat small mesenteric arteries. The vasorelaxant efficacy and potency of
vCGRP were similar to that of CGRP, in activating CGRP receptors and Kv channels to relax arteriole
smooth muscle, which would facilitate blood meal feeding by promoting continual blood flow. Our
results provide, for the first time, a detailed investigation into the identification and function of
a vasodilatory peptide found in D. rotundus venom, which provides a basis in understanding the
convergent pathways and selectivity of hematophagous venoms. These unique peptides also show
excellent drug design and development potential, thus highlighting the social and economic value of
venomous animals.
Keywords: vasodilatation; potassium channels; Desmodus rotundus; vampire bat; venom; calcitonin
gene-related peptide
Key Contribution: In this study, we identified a compound from D. rotundus venom (vCGRP)
that induces vasodilation of resistance vessels such as mesenteric arteries partly via voltage-gated
potassium channels and endothelium independent mechanisms. The human form of CGRP is a
potent vasodilator that acts partially via endothelium dependent and independent mechanisms.
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Hence, the selectivity of vCGRP could be used for therapeutic interventions in diseases such as
hypertension and diabetes.
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2. Results
2.1. Vasorelaxant responses to D. rotundus vCGRP and rCGRP.

treatment with L-NAME (100 μM) (Figure 3A). In contrast, potency to rCGRP was decreased 5-fold
in the presence of L-NAME (100 μM) from 9.16 ± 0.17 to 8.62 ± 0.09 (pEC50 = 0.01) with no difference
in maximum relaxation (Figure 3D). The presence of the soluble guanylyl cyclase inhibitor ODQ (10
μ or the adenylyl cyclase inhibitor SQ22536 (10 μM) (Figure 3B−C, E−F) had no significant effect
on D.
rotundus
Toxins
2019,
11, 26 vCGRP or rCGRP relaxation curves.
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2.3. Contribution of potassium channels to D. rotundus vCGRP and rCGRP mediated relaxation.
2. Results
Raising the extracellular concentration of K+ to 30 mM markedly attenuated the relaxant
response
to D.Responses
rotundusto vCGRP
(Figure
4A).
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D. rotundus
vCGRP
and Blocking
rCGRP voltage-dependent K+ channels with
4-aminopyridine (1 mM) markedly attenuated D. rotundus vCGRP-induced relaxation, reducing the
In rat small mesenteric arteries, D. rotundus vCGRP was a potent vasorelaxant (pEC50 = 9.47 ± 0.32
potency by approximately 30-fold (p < 0.05) and reducing the response at 10 nM to 53.7
± 17.3% (p <
−logM, Rmax = 94.6 ± 2.4%) with a potency and efficacy similar to that of rat calcitonin gene-related
0.01). However, vasorelaxation to D. rotundus vCGRP was unchanged in the presence of the
peptide (rCGRP; +pEC50 = 9.16 ± 0.17 -logM Rmax = 93.8 ± 2.6; Figure2+2A). In the presence
of the rat
ATP-sensitive K channel inhibitor, glibenclamide (10 μM), or the Ca activated K+ channel inhibitor,
CGRP1 receptor antagonist CGRP8-37, the potency of D. rotundus vCGRP (Figure 2B) and rCGRP
TEA (1 mM). Similarly, vasorelaxation to rCGRP was attenuated in the presence of 30 mM K+ or
(Figure 1C) was decreased by 6-fold (p < 0.05) and 5-fold (p < 0.05) respectively, with no change in
4-aminopyridine (1 mM) yet unchanged in the presence of TEA (1 mM) or glibenclamide (10 μM)
Rmax (Figure 2B).
(Figure 4B).
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2.2. Contribution of NO-SGC and Adenylate Cyclase to D. rotundus vCGRP and rCGRP Mediated Relaxation
3. Discussion
Vasorelaxation to D. rotundus vCGRP was unchanged following endothelial denudation or
D. rotundus venom is well known to contain anticoagulating properties in order to facilitate
treatment with L-NAME (100 µM) (Figure 3A). In contrast, potency to rCGRP was decreased 5-fold in
blood feeding [26]. Indeed, a glycoprotein, Draculin, which inhibits activated coagulation factors IX
the presence of L-NAME (100 µM) from 9.16 ± 0.17 to 8.62 ± 0.09 (pEC50 = 0.01) with no difference
(IXa) and X (Xa) has been isolated from D. rotundus venom [5]. In the current study, we isolated and
in maximum relaxation (Figure 3D). The presence of the soluble guanylyl cyclase inhibitor ODQ
characterised a peptide (vCGRP) from the venom, which is similar in size and amino acid sequence
(10 µM) or the adenylyl cyclase inhibitor SQ22536 (10 µM) (Figure 3B,C,E,F) had no significant effect
to CGRP found in humans and rats. CGRP is a potent vasodilator that acts via activation of CGRP1
on D. rotundus vCGRP or rCGRP relaxation curves.
2.3. Contribution of Potassium Channels to D. rotundus vCGRP and rCGRP Mediated Relaxation
Raising the extracellular concentration of K+ to 30 mM markedly attenuated the relaxant response
to D. rotundus vCGRP (Figure 4A). Blocking voltage-dependent K+ channels with 4-aminopyridine
(1 mM) markedly attenuated D. rotundus vCGRP-induced relaxation, reducing the potency by
approximately 30-fold (p < 0.05) and reducing the response at 10 nM to 53.7 ± 17.3% (p < 0.01).
However, vasorelaxation to D. rotundus vCGRP was unchanged in the presence of the ATP-sensitive
K+ channel inhibitor, glibenclamide (10 µM), or the Ca2+ activated K+ channel inhibitor, TEA (1 mM).
Similarly, vasorelaxation to rCGRP was attenuated in the presence of 30 mM K+ or 4-aminopyridine
(1 mM) yet unchanged in the presence of TEA (1 mM) or glibenclamide (10 µM) (Figure 4B).
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3. Discussion

(endothelium-independent) [33–38]. However, the presence of ODQ (guanylyl cyclase inhibitor)
or SQ22536 (adenylyl cyclase inhibitor), had no significant effect on rCGRP or D. rotundus vCGRP
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or rat CGRP tested in pig coronary leads to increased cAMP and causes vasorelaxation via
endothelium-independent pathways [34]. However, human CGRP tested in human vessels are
endothelium-dependent [28].
Therefore, we next sought to characterise the mechanism(s) via which vCGRP mediates
endothelium-independent relaxation. Our finding that raising the extracellular K+ concentration
to 30 mM markedly attenuated the relaxation to vCGRP suggests that the peptide modulates relaxation
of rat small mesenteric arteries in part via activation of K+ channels. Indeed, we identified an ability of
vCGRP to activate voltage-dependent K+ channels as relaxation responses were decreased by 4-AP.
This was in agreement to findings with respect to rCGRP. Neither KATP nor KCa channels appeared
to be involved in relaxation to vCGRP or rCGRP as glibenclamide and TEA were without effect.
Indeed, there is evidence that activation of CGRP receptors could lead to direct opening of K+ channels,
in particular Kv channels [33]. There are conflicting reports on the involvement of KATP and KCa
channels in vasorelaxation, which could be related to the type of vessel studied. For instance, studies
using bovine retinal arteries and rabbit mesenteric arteries report that activation of KATP channels, but
not KCa channels, leads to vasorelaxation [37,39,40]. However, studies in smooth muscle cells from
rat mesenteric arteries have shown CGRP directly activates BKCa channels [41]. These data further
highlight that CGRP causes vasorelaxation through a variety of mechanisms which is dependent upon
the species and vessel involved.
Considering the medical relevance to humans of D. rotundus and other vampire bat species as
disease vectors for rabies [1], it is surprising that more in depth studies have not been conducted
on the intricate mechanisms employed in their feeding behaviour, despite studies on other blood
feeding animals such as fleas and leeches [13,26,42]. Such secretions fit within the definition of
venom as ‘A secretion produced in specialized cells in one animal, delivered to a target animal
through the infliction of a wound and that disrupts endophysiological or biochemical processes in
the receiving animal to facilitate feeding, defense or competition by/of the producing animal’ [42].
As peptides used by venoms/hematophagous-secretions are modified versions of those routinely
expressed in other tissues [43] future work including the other two species of vampire bat and
non-hematophagous bats would be enlightening in regards to the timing of the recruitment for
use in blood-feeding and the molecular diversification events. This study has opened the way for
further research to investigate the pathways and intricate mechanisms of hematophagous venoms,
in particular vampire bats. Therefore, we have made clear the ability of vCGRP to selectively mediate
endothelium-independent vasorelaxation in part via activation of Kv channels.
This selectivity of vCGRP to target only vascular smooth cells (similar to that of human CGRP)
highlights the interesting possibility that vCGRP may confer benefit in the context of cardiovascular
diseases such as hypertension, heart failure and kidney diseases [44]. Further functional studies are
required for vCGRP to become a therapeutic intervention with potential pharmacological applications.
This research also paves the way for further evolutionary studies into hematophagous venoms.
4. Materials and Methods
Synthesis of vCGRP was accomplished using protocols previously described by us for other
peptides [45].
4.1. Isolation of Rat Small Mesenteric Arteries
Male Sprague-Dawley rats (200–250 g) were euthanized via CO2 inhalation (95% CO2 , 5%
O2 ) followed by exsanguination. Small mesenteric arteries (second-order branch of the superior
mesenteric artery) were isolated, cut into 2 mm lengths, and mounted on 40 µm wires in small vessel
myographs [46]. Vessels were maintained in physiological salt solution [composed of (in mM) 119 NaCl,
4.7 KCl, 1.17 MgSO4 , 25 NaHCO3 , 1.8 KH2 PO4 , 2.5 CaCl2 , 11 glucose, and 0.026 EDTA] at 37 ◦ C and
were bubbled with carbogen (95% O2 , 5% CO2 ). In a subset of arteries, the endothelium was gently
denuded via insertion of a 40 µm wire inside the lumen and rubbing the vessel walls. The mesenteric
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arteries were allowed to equilibrate for 30 min under zero force and then a 5 mN resting tension was
applied. Changes in isometric tension were recorded using Myograph Interface Model 610 M version
2.2 (DMT, Aarhus, Denmark) and PowerLab/835 (ADInstruments Inc, Bella Vista, NSW, Australia).
Data was recorded with the data acquisition program Chart (V5, ADInstruments). Following a 30 min
equilibration period at 5 mN, the mesenteric arteries were contracted maximally (Fmax ) using a K+
depolarizing solution [K+ −containing physiological salt solution (KPSS); composed of (in mM) 123 KCl,
1.17 MgSO4 , 1.18 KH2 PO4 , 2.5 CaCl2 , 25 NaHCO3 , and 11 glucose]. The integrity of the endothelium
was confirmed by relaxation to acetylcholine (ACh, 10 µM) [46] in tissues pre-contracted with the
thromboxane A2 mimetic, U46619 (1 µM) [46]. Arteries were washed with physiological salt solution
and the tension allowed to return to baseline.
4.2. Vasorelaxation Experiments
Cumulative concentration-response curves to D. rotundus vCGRP (10−12 –3 × 10−8 M) or rCGRP
(3 × 10−12 –10−8 M) [32,34,37] were constructed in vessels pre-contracted submaximally (~50% Fmax)
with titrated concentration of U46619 (0.01 µM–0.2 µM). Responses to D. rotundus vCGRP and rCGRP
were obtained in endothelium-intact mesenteric arteries in the absence or presence of either ODQ
(10 µM) [47], SQ22536 (10 µM) [48], L-NAME (0.1 µM) [46], CGRP8-37 (0.1 µM) [49,50], 30 mM K+ [33],
TEA (1000 µM), 4-aminopyridine (1000 µM) [46] or glibenclamide (10 µM) [32,51]. All treatments were
added for 30 min prior to precontraction with U46619. In a subset of endothelium-denuded arteries,
vasorelaxation to D. rotundus vCGRP was also examined. Sodium nitroprusside (SNP; 10 µM) [47]
was added at the end of each concentration-response curve to ensure maximum relaxation. Only
one concentration-response curve to D. rotundus vCGRP or rCGRP was obtained in each vessel
segment [47,52].
4.3. Data Analysis and Statistical Procedures
Relaxation responses were expressed as a percentage reversal of the U46619 pre-contraction.
Individual relaxation curves were fitted to a sigmoidal logistic equation and pEC50 values
(concentration of agonist resulting in a 50% relaxation) calculated and expressed as –Log mol.L−1 .
Statistical comparisons between the experimental groups’ mean pEC50 and maximum relaxation
(Rmax ) values were made using a Student’s unpaired t-test or one-way ANOVA with Bonferroni’s
post hoc comparison. Where pEC50 values could not be obtained, concentration-response curves were
compared by means of a two-way ANOVA. n = number of artery segments from separate animals.
Data represent the mean ± SEM (error bars on graph). Statistical significance was defined as * p < 0.05.
All data analysis was performed using GraphPad Prism version 5.02 (GraphPad Software, San Diego,
CA, USA, 2009) [46].
4.4. Reagents
Reagents and their sources were U46619 (Cayman Chemical company, Ann Arbor, Michigan,
USA), SQ22356 (Tocris bioscience, Bristol, UK), ODQ, Glibenclamide, TEA, 4-aminopyridine, L-NAME,
SNP, ACh, CGRP8-37 (Sigma-Aldrich, St Louis, MO, USA), and CGRP (rat) Peptide Institute, Osaka,
Japan. Stock solutions of ODQ (10 mmol/L) and U46619 (1 mM) were dissolved in absolute ethanol.
All subsequent dilutions of stock solutions were in distilled water. All other drugs were made up in
distilled water and all dilutions were prepared fresh daily.
Author Contributions: Conceptualization, B.G.F. and B.K.K.-H.; Methodology, B.G.F., B.K.K.-H. and R.K.;
validation, B.K.K.-H., R.K. and R.R.; formal analysis, B.K.K.-H. and R.K.; investigation, B.G.F., B.K.K.-H. and
R.K.; resources, B.G.F., A.A., A.B., P.F.A., and B.H.; data curation, B.K.K.-H. and R.K.; writing—original draft
preparation R.K.; writing—review and editing, W.C.H., R.J.H., B.K.K.-H., B.G.F., and R.K.; visualization, B.G.F.,
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